Several new industry groups have joined the Australian Medtech Manufacturing Alliance (AMMA).
Led by BioMelbourne Network, the new initiative brings together expertise from peak industry bodies and companies to create a voice and advocate on behalf of Victorian medtech manufacturers across the key issues impacting the sector.
The groups are Pathology Technology Australia (PTA), the Association of Healthcare Supply and Procurement Officers (AHSPO) and the Medical Technology Association of Australia (MTAA).
The AMMA has been seed-funded by the Victorian Government.
BioMelbourne Network CEO and AMMA lead Karen Parr said, “With industry and health two sides to the same coin, it’s critical to the Alliance’s success to have both perspectives in the room to drive meaningful outcomes.
“Combining PTA’s deep knowledge of in vitro diagnostics (IVDs), MTAA’s expertise traversing medtech companies and procurement, and AHSPO’s expertise in healthcare supply chain and procurement, in addition to the experience held within MTPConnect, AMTIL, AusBiotech, and Victoria’s Industry Capability Network, unites the pipeline. It adds even greater strength to our vigorous advocacy for systemic improvements in procurement pathways and market access for locally made medtech products.”
THe AMMA will focus on improving procurement pathways, unified advocacy, driving policy changes to support local innovation and sovereign capabilities, and strengthening ties between manufacturers, diagnostic providers, and healthcare stakeholders.
Dean Whiting, CEO of Pathology Technology Australia, highlighted the significance of the partnership: “Joining AMMA allows us to collaborate across the medtech ecosystem and ensure that diagnostics and pathology remain at the forefront of healthcare innovation in Australia. We cannot hope to be self-sfficient in all areas of pathology technology, but we can be a centre of excellence in the fast grown Asia/Pacific market for a few key technologies.”
Aldo Santo, President of AHSPO, said, “As a national organisation dedicated to healthcare supply and procurement, we are delighted to collaborate with AMMA. This partnership represents an important step toward fostering stronger, more connected pathways for locally manufactured medtech. By tackling procurement challenges directly, we aim to ensure that Australian healthcare providers and patients fully benefit from the outstanding innovations being developed right here in our country.”
MTAA CEO Ian Burgess added, “MTAA is proud to join AMMA in this collaborative effort to strengthen Australia’s medtech industry. By uniting our resources and expertise, we can advocate more effectively for policies that support local manufacturing, improve procurement processes and ensure that Australian patients have access to the latest medical technologies.”
